Phase III Study of pembrolizumab in locally advanced Stage III NSCLC

• Research type

  Research Study

• Full title

  A Phase 3 Study of Pembrolizumab (MK-3475) in Combination with Concurrent Chemoradiation Therapy Followed by Pembrolizumab with or without Olaparib vs Concurrent Chemoradiation Therapy Followed by Durvalumab in Participants with Unresectable, Locally Advanced, Stage III Non-Small Cell Lung Cancer (NSCLC)

• IRAS ID

  1003218

• Contact name

  Crispin Hiley

• Contact email

  crispinhiley@nhs.net

• Eudract number

  2019-003237-41

• Clinicaltrials.gov Identifier

  NCT04380636

• REC name

  South West - Central Bristol Research Ethics Committee

• REC reference

  20/SW/0073

• Date of REC Opinion

  11 Jun 2020

• REC opinion

  Further Information Favourable Opinion